Clinical Trial Update: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ALK-rearranged non-small cell lung cancer evaluating pembrolizumab plus bevacizumab and chemotherapy, with the study currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: ALK Gene Mutation, Lung Adenocarcinoma | Phase 2 | Status: RECRUITING